IL-6 assists tumor cells’ survival with TME manipulation as well as downregulation of CD8+ T cells, macrophage M1 to M2 phenotype changes and upregulation of immune-suppressing cells such as T helper 17 (Th17), Tregs, and myeloid-derived suppressive cells (MDSCs) [106]. Here, CD8A is linked to neoplasm.